May 22, 2020 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from January 24, 2020 (vote required)
2. Approval of minutes from January 24, 2020 (vote required)
»
3. Announcement: Drug Utilization Review Board Conflict of Interest Policy Review
3. Announcement: Drug Utilization Review Board Conflict of Interest Policy Review
»
4. New business: » - a. Anti-allergens, oral b. Antibiotics, inhaled c. Anticoagulants d. Antidepressants, other e. Antidepressants, selective serotonin reuptake inhibitors f. Antidepressants, tricyclic g. Antihyperuricemics h. Antiparkinsons agents i. Antivirals, oral/nasal j. Anxiolytics k. Beta blockers l. Bile salts m. Benign prostatic hyperplasia treatments n. Bronchodilators, beta agonist o. Chronic obstructive pulmonary disease agents p. Cough and cold agents q. Erythropoiesis stimulating proteins r. Glucagon agents s. Glucocorticoids, inhaled t. Hereditary angioedema treatments u. Immune globulins, intravenous v. Immunomodulators, asthma w. Lincosamides/oxazolidinones/streptogramins x. Lipotropics, other y. Lipotropics, statins z. Pulmonary arterial hypertension agents, oral and inhaled aa. aa.Pancreatic enzymes ab. bb.Pediatric vitamin preparations ac. cc.Prenatal vitamins ad. dd.Sedative hypnotics ae. ee.Sickle cell anemia treatments af. ff.Thrombopoiesis stimulating proteins ag. gg.Urea cycle disorder, oral
4. New business: »
a. Anti-allergens, oral b. Antibiotics, inhaled
c. Anticoagulants
d. Antidepressants, other
e. Antidepressants, selective serotonin reuptake inhibitors
f. Antidepressants, tricyclic
g. Antihyperuricemics
h. Antiparkinsons agents
i. Antivirals, oral/nasal
j. Anxiolytics
k. Beta blockers
l. Bile salts
m. Benign prostatic hyperplasia treatments
n. Bronchodilators, beta agonist
o. Chronic obstructive pulmonary disease agents
p. Cough and cold agents
q. Erythropoiesis stimulating proteins
r. Glucagon agents
s. Glucocorticoids, inhaled
t. Hereditary angioedema treatments
u. Immune globulins, intravenous
v. Immunomodulators, asthma
w. Lincosamides/oxazolidinones/streptogramins
x. Lipotropics, other
y. Lipotropics, statins
z. Pulmonary arterial hypertension agents, oral and inhaled
aa. aa.Pancreatic enzymes
ab. bb.Pediatric vitamin preparations
ac. cc.Prenatal vitamins
ad. dd.Sedative hypnotics
ae. ee.Sickle cell anemia treatments
af. ff.Thrombopoiesis stimulating proteins
ag. gg.Urea cycle disorder, oral
»
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid preferred drug list: » - a. Absorica LD (oral) / Acne agents, oral b. Reyvow (oral) / Antimigraine agents, other c. Ubrelvy (oral) / Antimigraine agents, other d. Secuado (transdermal) / Antipsychotics agents e. Gabacaine Kit (miscellaneous) / Neuropathic pain agents f. Ziextenzo syringe (subcutaneous) / Colony stimulating
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid preferred drug list: »
a. Absorica LD (oral) / Acne agents, oral b. Reyvow (oral) / Antimigraine agents, other
c. Ubrelvy (oral) / Antimigraine agents, other
d. Secuado (transdermal) / Antipsychotics agents
e. Gabacaine Kit (miscellaneous) / Neuropathic pain agents
f. Ziextenzo syringe (subcutaneous) / Colony stimulating
»
6. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
6. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
»
7. Executive work session
7. Executive work session
»
8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
»
9. Retrospective DUR: Mariya Baranova, Pharm. D., MCMP-II, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Prevention of adverse drug events in patients receiving opioids ii. Pain management with opioids iii. Monitoring of psychotropic drugs in youth b. Report on recent retrospective DUR intervention outcomes: i. Psychotropic drugs in adults ii. Medication adherence iii. Mental health disorder therapy management iv. Respiratory disease management c. Retrospective DUR proposals (vote required) i. Asthma ii. Nonsteroidal anti-inflammatory drugs (NSAIDS) iii. Post-traumatic stress disorder (PTSD)
9. Retrospective DUR: Mariya Baranova, Pharm. D., MCMP-II, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Prevention of adverse drug events in patients receiving opioids
ii. Pain management with opioids
iii. Monitoring of psychotropic drugs in youth
b. Report on recent retrospective DUR intervention outcomes:
i. Psychotropic drugs in adults
ii. Medication adherence
iii. Mental health disorder therapy management
iv. Respiratory disease management
c. Retrospective DUR proposals (vote required)
i. Asthma
ii. Nonsteroidal anti-inflammatory drugs (NSAIDS)
iii. Post-traumatic stress disorder (PTSD)
»
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., BCPS, KEPRO, LLC (vote required) » - a. Monoclonal antibody agents for asthma - new criteria b. Ophthalmic immunomodulators - new criteria c. Transthyretin agents - new criteria d. Tricyclic antidepressants - new criteria
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., BCPS, KEPRO, LLC (vote required) »
a. Monoclonal antibody agents for asthma - new criteria b. Ophthalmic immunomodulators - new criteria
c. Transthyretin agents - new criteria
d. Tricyclic antidepressants - new criteria
»
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) » - a. Benzodiazepines (not including sedative/hypnotics) b. Complement inhibitor and enzyme/protein replacement therapy c. Direct oral anticoagulants d. Hydroxy-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors e. Low-molecular-weight heparins f. Nebulized bronchodilators
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) »
a. Benzodiazepines (not including sedative/hypnotics) b. Complement inhibitor and enzyme/protein replacement therapy
c. Direct oral anticoagulants
d. Hydroxy-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors
e. Low-molecular-weight heparins
f. Nebulized bronchodilators
»
Items 12 & 13 » - 12. Next meeting date: July 24, 2020 13. Adjourn
Items 12 & 13 »
12. Next meeting date: July 24, 2020 13. Adjourn
